Neurogene Advances Rett Gene Therapy Toward BLA With Strong Cash Runway

Neurogene ( (NGNE) ) has provided an announcement.

Neurogene reported full-year 2025 results as it advances NGN-401, a gene therapy for Rett syndrome, through its Embolden registrational trial, where enrollment is now complete and more than half of participants have been dosed. NGN-401 has been generally well-tolerated at the 1E15 vg dose with no HLH cases, has secured FDA Breakthrough Therapy designation, and is supported by payor research suggesting strong reimbursement potential.

The company plans to complete Embolden dosing in the second quarter of 2026, present updated interim Phase 1/2 data mid-2026, and initiate a Process Performance Qualification campaign to support BLA readiness, aided by FDA alignment that commercial and clinical manufacturing scales are identical. Backed by $269 million in cash and equivalents, a higher 2025 R&D spend driven by Rett trial activity, and runway into early 2028, Neurogene is ramping early commercial-readiness efforts despite posting a wider annual net loss as it positions NGN-401 for a potential biologics license application and launch.

The most recent analyst rating on (NGNE) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Neurogene stock, see the NGNE Stock Forecast page.

Spark’s Take on NGNE Stock

According to Spark, TipRanks’ AI Analyst, NGNE is a Neutral.

The score is held down primarily by weak financial performance (no TTM revenue, widening losses, and sizable cash burn) and bearish technicals (trading below key moving averages with negative MACD). These are partially offset by a strong balance sheet and positive clinical/regulatory progress in NGN-401 that supports the longer-term thesis but does not yet reduce near-term execution and funding risk.

To see Spark’s full report on NGNE stock, click here.

More about Neurogene

Neurogene Inc. is a clinical-stage biotechnology company focused on developing gene therapies for rare neurological diseases, with its lead program NGN-401 targeting Rett syndrome. The company is advancing NGN-401 through registrational and Phase 1/2 trials, while preparing commercial manufacturing and market access strategies for a potential launch in the U.S. and beyond.

Average Trading Volume: 168,510

Technical Sentiment Signal: Sell

Current Market Cap: $299.9M

For a thorough assessment of NGNE stock, go to TipRanks’ Stock Analysis page.